Smithbridge Asset Management Inc. DE Sells 100,198 Shares of Novo Nordisk A/S $NVO

Key Points

• Smithbridge Asset Management cut its Novo Nordisk stake by 50.3% in the first quarter, selling 100,198 shares and leaving it with 98,990 shares worth about $3.64 million.
• Novo Nordisk reported solid quarterly results, with $1.03 EPS and $10.85 billion in revenue, while analysts expect the company to earn 3.41 EPS for the current year.
• Recent catalysts for the stock include temporary Medicare coverage for GLP-1 obesity treatments like Wegovy, a manufacturing partnership in India, and a Nordea upgrade to Buy.

Smithbridge Asset Management Inc. DE cut its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 50.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 98,990 shares of the company's stock after selling 100,198 shares during the period. Smithbridge Asset Management Inc. DE's holdings in Novo Nordisk A/S were worth $3,638,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at about $25,000. WealthCollab LLC increased its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $28,000. Maseco LLP bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $48.69 on Thursday. The company has a market capitalization of $217.40 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 4.33 and a beta of 0.77. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79. The stock's 50 day moving average is $44.25 and its 200-day moving average is $45.81.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts expect that Novo Nordisk A/S will post 3.41 EPS for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Medicare is starting temporary coverage for GLP-1 obesity treatments, including Novo Nordisk’s Wegovy injection and tablet, which could broaden access and increase demand for the company’s weight-loss drugs. Medicare will start covering obesity drugs for the first time. Here's what patients should know
• Positive Sentiment: Shantha Biologics announced an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India, a move that could help strengthen supply and support future product demand. Shantha Biologics Announces Cartridge Fill-Finish Collaboration
• Positive Sentiment: Nordea upgraded Novo Nordisk to Buy, signaling improved analyst confidence in the stock’s valuation and dividend appeal. Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why
• Positive Sentiment: Shares also rose after the company was highlighted as outperforming the broader market in recent trading, reflecting investor appetite for the name amid obesity-drug optimism. Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: News coverage around weight-loss ETFs and broader obesity-treatment investing reinforces sector interest, but it is more of a thematic tailwind than a direct catalyst for Novo Nordisk. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS estimate slightly, which is a modest cautionary note, though it did not change the broader longer-term growth story. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Wall Street Analyst Weigh In

Several brokerages have recently commented on NVO. Weiss Ratings downgraded Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, April 22nd. Nordea Equity Research upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Friday, June 19th. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an "outperform" rating and a $175.00 price target for the company. TD Cowen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price objective for the company. in a research report on Tuesday, March 10th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Five research analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.